Phase 3 Trial of Tarlatamab (SC vs IV) in Extensive-Stage Small Cell Lung Cancer After Platinum Based First-line Chemotherapy (ES-SCLC)

Study acronym: DeLLphi-315
StatusRecruiting
PhasePhase 3
SponsorAmgen
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial sites expanded: 2 → 9 locations
    • Start date changed from estimate of Aug 31, 2026 to Aug 28, 2026
    • Eligibility criteria expanded, about 30 words
  2. Study First Submitted
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Amgen
174 trials monitored
See 10 trials at risk
Lung Cancer
4,822 trials monitored
See 267 trials at risk
Small Cell Lung Cancer
570 trials monitored
See 34 trials at risk
The primary objective of this study is to demonstrate non-inferiority in pharmacokinetic (PK) parameters of subcutaneous (SC) vs intravenous (IV) tarlatamab administration and to characterize the efficacy, safety, and tolerability of SC tarlatamab in participants with relapsed extensive-stage small-cell lung cancer (ES-SCLC) after platinum-based chemotherapy.
Trial Details
NCT Number NCT07778316
Lead Sponsor Amgen
Conditions
(from sponsor)		 Small Cell Lung Cancer
Related terms Small Cell Lung Carcinoma
Enrollment 400 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov